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study question: How many infertile men who wish to conceive need to be screened for chromosomal abnormalities to prevent one
miscarriage or the birth of one child with congenital anomalies (CAs)?
summary answer: In azoospermic men, the prevalence of chromosomal abnormalities is 15.2% and the number needed to be
screened (NNS; minimum–maximum estimate) for a miscarriage is 80–88 and for a child with CAs is 790–3951. The prevalence of chromo-
somal abnormalities in non-azoospermic men is 2.3% and the NNS are 315–347 and 2543–12 723, respectively.
what is known already: Guidelines advise the screening of infertile men for chromosomal abnormalities to prevent miscarriages
and children with congenital abnormalities, but no studies have been published on the effectiveness of this screening strategy.
study design, size, duration: Retrospective cohort study of 1223 infertile men between 1994 and 2007.
participants, setting, methods: Men with azoospermia and men eligible for ICSI treatment visiting a university hospital fer-
tility clinic in The Netherlands who underwent chromosomal analysis between 1994 and 2007 were identiﬁed retrospectively in a registry.
Only cases of which at least one sperm analysis was available were included. Data were collected by chart review, with a follow-up of preg-
nancies and their outcomes until 2010. The chromosomal abnormalities were categorized according to their risk of unbalanced offspring,
i.e. miscarriage and/or child with CAs. Multi-level analysis was used to estimate the impact of chromosomal abnormalities on the
outcome of pregnancies in the different subgroups of our cohort. NNS for miscarriages and children with CAs were calculated based on
data from our cohort and data published in the literature.
main results and the role of chance: A chromosomal abnormality was found in 12 of 79 men with azoospermia (15.2%)
and in 26 of 1144 non-azoospermic men (2.3%). The chromosomal abnormalities were categorized based on the literature, into abnormal-
ities with and abnormalities without increased risk for miscarriage and/or child with CAs. In our study group, there was no statistically sig-
niﬁcant difference between the subgroups with and without increased risk respectively, regarding the frequency of children born with CAs
(1/20; 5.0% versus 1/14; 7.1%), miscarriage (9/20; 45.0% versus 2/14; 14.3%) or unaffected liveborn children (9/20; 45.0% versus 9/14;
64.3%). The prevalence of chromosomal abnormalities with a theoretically increased risk of unbalanced progeny was 1.0% in non-azoosper-
mic men and 3.8% in men with azoospermia. For the calculation of the NNS, the risk of an adverse pregnancy outcome in our cohort was
compared with the incidence ranges of miscarriage and children with CAs in the general population. The number of azoospermic men that
needs to be screened to prevent one miscarriage (80–88) or one child with CAs (790–3951) was considerably lower compared with the
NNS in the non-azoospermic group (315–347 and 2543–12 723, respectively).
& The Author 2012. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
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limitations, reason for caution: The prevalence of chromosomal abnormalities in infertile men is low, and although we
included 1223 men, our conclusions are based on a small number (38) of abnormal karyotypes. As there are no large series on outcomes
of pregnancies in infertile men with chromosomal abnormalities, our conclusions had to be partly based on assumptions derived from the
literature.
wider implications of the findings: Based on the NNS calculated in our study, screening for chromosomal abnormalities is
recommended in all azoospermic men. In non-azoospermic infertile men, screening might be limited to men with an additional risk factor
(e.g. a history of recurrent miscarriage or a positive family history for recurrent miscarriage or children with CAs). The NNS can be used in
future cost-effectiveness studies and the evaluation of current guidelines on karyotyping infertile men.
study funding/competing interest(s): Our institution has received research grants from Merck Sharpe & Dohme BV,
Ferring Pharmaceuticals and Merck Serono, The Netherlands. No competing interests declared.
Key words: chromosomal abnormalities / miscarriage / congenital anomalies / male infertility
Introduction
The prevalence of chromosomal abnormalities and submicroscopic
deletions of the Y chromosomal azoospermia factor (AZF) region is
increased in infertile men (summarized by O’Flynn O’Brien et al.,
2010). Because of this increased prevalence, guidelines recommend
screening for these genetic abnormalities before ICSI treatment in
case of (severe) male infertility (NVOG, 1999; Crosignani and
Rubin, 2000; Foresta et al., 2002; NICE, 2004; AUA and ASRM,
2006). However, these guidelines are not based on clinical data and
cost-effectiveness studies. So far, no studies have been published on
the prevalence of adverse pregnancy outcomes in large cohorts of in-
fertile men with genetic abnormalities.
The detection of a chromosomal abnormality in men with poor
sperm quality allows clinicians to counsel the couple, not only regard-
ing their chance of achieving a viable pregnancy with or without
assisted reproductive technology (ART), but also on recurrent miscar-
riages or the risk of a child with congenital anomalies (CAs). The as-
sociation between the latter two and balanced chromosomal
rearrangements in particular, is well established (Tharapel et al.,
1985; Egozcue et al., 2000; Suzumori and Sugiura-Ogasawara, 2010).
The risk for a couple of having a child with an unbalanced karyotype
depends on the segregation behaviour of the derivative chromosomes
during meiosis and the size and nature of the translocated or inverted
chromosome segments.
In a previous study, we found a low prevalence of chromosomal ab-
normalities in a cohort of 1223 men who were azoospermic or eligible
for ICSI treatment (3.1%) (Dul et al., 2010). There was a signiﬁcant
difference in the prevalence of chromosomal abnormalities between
azoospermic men (15.2%) and non-azoospermic men (2.3%) (Dul
et al., 2012). The question whether or not to perform chromosomal
analysis in infertile men not only depends on the prevalence of
chromosomal abnormalities, but also on the consequences of these
abnormalities. To explore the consequences, we addressed two ques-
tions in the present study: (i) Was ART performed in couples in which
the male partner carried a chromosomal abnormality and what were
the outcomes? (ii) Does the detected chromosomal abnormality have
clinical relevance for the progeny of the couple and what would be the
consequences if the abnormality had remained undetected? The aim
of this study was to assess, by answering these questions for azoosper-
mic and non-azoospermic men separately, the efﬁciency of screening
infertile men for chromosomal abnormalities in terms of estimating
the risk of an adverse pregnancy outcome. Therefore, we calculated
the numbers needed to be screened (NNS) to have the option to
prevent a miscarriage or the birth of a child with CA.
Materials and Methods
Our cohort consisted of men with azoospermia or eligibility for ICSI treat-
ment who visited the fertility clinic of the University Medical Center Gro-
ningen between November 1994 and October 2007. Azoospermia and
non-azoospermia were determined based on the ﬁrst sperm analysis in
our centre, as described in detail previously (Dul et al., 2010). In 1223
men, the results of chromosomal analysis were available. Data on ART,
ART related and spontaneous pregnancies (with a follow-up until 2010)
and their outcomes were collected by chart review. In the study period,
only ART with ejaculated sperm was offered in our centre.
No ethical board approval is required for retrospective chart review and
collection of anonymized data in The Netherlands. Infertile couples
attending our clinic are informed at intake about possible use of their
anonymized data for research purposes, and a ‘no objection procedure’
is followed. Only patients who had not objected participated in this study.
Chromosomal analysis
Chromosomal analysis was performed on cultured peripheral lympho-
cytes. Five GTG-banded metaphase spreads with a minimal banding reso-
lution of 550 were analysed per patient. In case of numerical mosaics, 100
metaphases were examined by conventional microscopic screening or
FISH. When structural chromosomal aberrations were present, the evalu-
ation was extended to additional molecular cytogenetic analysis by FISH or
array comparative genomic hybridization, whenever appropriate. Chromo-
somal heteromorphisms as deﬁned in the International System for human
Cytogenetic Nomenclature 2009 were not considered chromosomal ab-
normalities (Shaffer et al., 2009).
Classiﬁcation of consequences
For each abnormality found, we performed a literature search for the risk
of transmitting a chromosomal imbalance to the progeny. The estimation
of the risk of unbalanced offspring is based on family history, and on pub-
lished data on the expected segregation pattern of the translocation chro-
mosomes and viability of the respective deletions and duplications
(Stengel-Rutkowski et al., 1988; Schinzel, 2001; Feenstra et al., 2006).
Based on these publications, we categorized the detected chromosomal
abnormalities into the following categories: Chromosomal abnormality
that does not increase the risk for miscarriage or a child with congenital
anomalies not increased (NI); Chromosomal abnormality that increases
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the risk of miscarriage (M); Chromosomal abnormality that increases the
risk of both miscarriage and a child with CAs (M and CA). The incidences
of miscarriages and of children with CA were compared between the
latter two categories combined (M + M and CA) versus the NI group.
Calculation of NNS and statistical analysis
The NNS represents the number of subjects to be tested to detect one
with a chromosomal abnormality that increases the risk for adverse preg-
nancy outcomes. For calculating NNS, the absolute difference in the risk of
an adverse event in the study group and the risk in a reference population
is calculated and the inverse of this risk difference is given as the NNS.
In order to calculate the NNS to prevent one miscarriage in infertile
men, we ﬁrst determined the incidence of miscarriage in the couples
with a male karyotype known to be associated with an increased risk of
miscarriage. However, not all miscarriages in this group will be due to
an unbalanced karyotype and thus a correction needs to be made. This
correction was based on the consistently reported incidence of clinically
recognizable miscarriage in general population studies (12–15%) (sum-
marized in Regan and Rai, 2000). Thus, the minimum NNS can be calcu-
lated as 1 divided by the prevalence of chromosomal abnormalities known
to be associated with an increased miscarriage risk times the incidence of
miscarriages in the study group minus the minimal reported general popu-
lation incidence of 12%. The maximum NNS will be 1 divided by the
prevalence times the incidence of miscarriages in the study group minus
the maximal reported population incidence of 15% (see Table I).
In order to calculate the NNS to prevent one child with CA, we used a
different strategy as the number of pregnancies in the couples with a male
chromosomal abnormality with an increased risk for a child with CA was
too small to reliably determine the incidence of children with CA. Instead,
we used the (theoretical) risk estimation for male carriers of a balanced
chromosomal abnormality with a known increased risk of viable offspring
with an unbalanced karyotype. In general, these risk ﬁgures may vary from
as low as 1% to well above 20%, depending on the particular translocation,
but the majority have a risk far below 5% (Stengel-Rutkowski et al., 1988;
Gardner and Sutherland, 2004). We conservatively estimated the risk of a
child with CA to be increased by 1–5% for the carriers of a translocation
with an assumed increased risk for CA. The estimated risk of 1–5% is the
extra risk due to the paternal chromosomal abnormality and is added to
the population risk of 3% of a child with CA. The minimum NNS for a
child with CA thus will be 1 divided by the prevalence of chromosomal
abnormalities related to an increased risk for CA times 5% and the
maximum NNS as 1 divided by the prevalence times 1% (see Table I).
Since the prevalence of chromosomal abnormalities in men with azoo-
spermia was signiﬁcantly higher than in men with non-azoospermia, we
calculated the NNS for both subgroups separately.
Statistical analysis was carried out using the Statistical Package for the
Social Sciences version 18.0 for Windows (SPSS Inc., Chicago, IL, USA).
Data were described in absolute counts and proportions. A generalized
estimating equation analysis was used to estimate the impact of chromo-
somal abnormalities on the outcome of pregnancies in our cohort,
accounting for the multi-level structure of the data, i.e. multiple pregnan-
cies in the same couple. As 3 of 31 pregnancies in our cohort were twin
pregnancies, we analysed the pregnancy outcomes per gestational sac
(GS). Effects with a P-value , 0.05 were considered statistically signiﬁcant.
Results
A chromosomal abnormality was detected in 38 of the 1223 men. The
chromosomal abnormalities found are listed per sperm concentration
category in Table II. In this table, the detected abnormalities are cate-
gorized according to their presumed consequences for progeny.
Table III summarizes the ART procedures and outcomes of preg-
nancies in our cohort of couples with a male chromosomal abnormal-
ity. In 21 of 26 couples with non-azoospermia, ART was started and
17 conceived. In two couples, a spontaneous pregnancy occurred.
Azoospermic men with a gonosomal abnormality (n ¼ 10) could not
be offered ART in our clinic and these couples did not conceive.
The remaining two azoospermic men [one with a reciprocal transloca-
tion (3;16) and one with a Robertsonian translocation (13;14) in com-
bination with an inversion of chromosome 5] showed some
spermatozoa in subsequent sperm analyses and ICSI treatment was
started. The ﬁrst couple did not conceive, but the latter did, which
resulted in the birth of a healthy child.
Table I Calculation of NNS for miscarriage (M) and for
a child with CA.
Formula number needed to screen
1: [prevalence of chromosomal abnormalities with increased risk
(incidence of adverse pregnancy outcome in study cohort—incidence in
reference population)]
Input parameters





Theoretical incidence of child with congenital anomalies in
men with a chromosomal abnormality with increased risk of a
child with congenital anomalies
4–8%
Incidence of child with congenital anomalies in general
population
3%





Incidence of miscarriage in men with a chromosomal
abnormality with increased risk for M
45%
Incidence of miscarriage in reference population 12–15%
Number needed to screen for congenital anomalies
Infertile men 1/[11/1223 × (0.082 0.03)]
to 1/[11/1223 × (0.04–0.03)]
2224–
11 123
Azoospermic men 1/[2/79 × (0.082 0.03)] to
1/[2/79 × (0.042 0.03)]
790–
3951
Non-azoospermic men 1/[9/1144 × (0.082 0.03)] to
1/[9/1144 × (0.042 0.03)]
2543–
12 723
Number needed to screen for miscarriage
Infertile men 1/[14/1223 × (0.452 0.12)]
to 1/[14/1223 (0.452 0.15)]
265–291
Azoospermic men 1/: [3/79 × (0.452 0.12)] to
1/[3/79 (0.452 0.15)]
80–88
Non-azoospermic men 1/[11/1144 × (0.452 0.12)]
to 1/[11/
1144 × (0.452 0.15)]
315–347
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Table II Chromosomal abnormalities per sperm concentration category found in a cohort of 1223 infertile men,
categorized according to presumed consequences for the offspring [Partially adapted from Dul et al. (2010)].
Abnormality type per
concentration category





Gonosomal 47,XXY (4 cases) NI






46,X,der(Y)(pter ≥ q11.223::p11 ≥ pter) NI
46,X,t(Y;18;20)(q11.2;q12.2;q13.3) M and CA
Translocation 46,XY,t(3;16)(q12;q23) M
Translocation and inversion 45,XY,inv(5)(p13.1q13.1),der(13;14)(q10;q10) M and CA
0–1 million/ml 3.1% (10/319)
Gonosomal 47,XXY NI
47,XYY (2 cases) NI
Mos 47,XYY/46,XY NI
Translocation 46,XY,t(1;14)(q44;q11.2) M and CA





1–5 million/ml 1.2% (3/251)
Gonosomal 47,XYY NI
Mos 47,XXY [2]/46,XY [17] NI
Inversion 46,XY,inv(10)(p11.2q21.2) M
5–10 million/ml 1.4% (3/211)
Translocation 46,XY,t(4:5)(q32;q14) M
46,XY,t(15;21)(q24;q22.3) M and CA
45,XY,der(13;14)(q10;q10) M and CA
10–20 million/ml 3.1% (6/191)
Gonosomal Mos 45,X [4]/46,XY [26] NI
Mos 45,X [3]/46,XY [27] NI
Mos 45,X [4]/46,XY [116] NI
Translocation 46,XY,t(3;11)(p21.3;q13) M and CA
45,XY,dic(13;14)(p11.2;p11.2) M and CA
45,XY,der(14;21)(q10,q10) M and CA
>20 million/ml 2.3% (4/172)
Translocation 46,XY,t(2;9)(q37.3;q12) M and CA
45,XY,der(15;21)(q10;q10) M and CA
Inversion 46,XY,inv(2)(p21q14.2) NI
46,XY,inv(11)(q21q23.3) NI
[n] represents number of cells within mosaic with that karyotype.
aNI: Chromosomal abnormality without increased risk for miscarriage or a child with congenital anomalies; M: Chromosomal abnormality with increased risk of miscarriage only;
M and CA: Chromosomal abnormality with increased risk of miscarriage and child with congenital anomalies.
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For our entire cohort of 1223 infertile men, the incidence of chil-
dren with CA was 3.1% (38/1211). This incidence did not differ signiﬁ-
cantly from the incidence in 38 infertile couples with a male
chromosomal abnormality, in which a child with CA was born to
two couples (2/34; 5.9%). One was attributable to the paternal kar-
yotype, but the other child had a normal karyotype, and the anomalies
could not be related to the paternal chromosomal abnormality. Eleven
of the 1223 men in our cohort carried a chromosomal abnormality
that theoretically increases the risk of a child with CA by 1–5%.
This is a conservative mean estimation based on a risk varying from
,1% in translocation (13;14) carriers to .5% in the carrier of trans-
location (1;14). To determine the number of infertile men that need to
be karyotyped to prevent one child with CA caused by a paternal
chromosomal abnormality, we used the formula in Table I. The
NNS in infertile men for one child with CA is 2224–11 123. In a popu-
lation of men with azoospermia, this NNS is 790–3951 and in non-
azoospermic men, 2543–12 723 (Fig. 1).
In our cohort, the incidence of a normal live born was 64.3% (9/14)
in the NI group, and 45.0% (9/20) in the M + M and CA group. This
difference was not statistically signiﬁcant. If ART was performed, the
chance for a couple of conceiving at least one normal live born was com-
parable in both groups (6/12; 47.4% and 6/11; 54.5%, respectively).
Six couples had one or more miscarriages. The incidence of miscar-
riages was higher in the M + M and CA group (9/20; 45.0%) com-
pared with the NI group (2/14; 14.3%; P ¼ 0.052). The incidence
of miscarriages in both groups was not statistically different from the
incidence of miscarriages in the men in our cohort with a normal kar-
yotype, which was 25.1% (304/1211) (data not shown). To determine
the number of infertile men that need to be karyotyped to ﬁnd one
miscarriage caused by a paternal chromosomal abnormality, we com-
pared the miscarriage rate of our M + M and CA couples (45.0%) to
the miscarriage rate in the general population (12–15%) (see Table I).
The NNS in infertile men for a miscarriage is 265–291. In men with
azoospermia the NNS is 80–88 and in non-azoospermic men,
315–347 (Fig. 1).
Discussion
The aim of this study was to assess the efﬁciency of screening infertile
men for genetic abnormalities in terms of estimating the risk of an
adverse pregnancy outcome (i.e. a child with CAs or a miscarriage).
These data are urgently needed as a basis for evidence-based guide-
lines on screening. Our ﬁndings are based on a large cohort of 1223
infertile men of whom 38 (3.1%) carried a chromosomal abnormality.
This relatively low prevalence is in agreement with reports from the
literature. However, no data are published on pregnancy outcomes
in large cohorts of infertile men with chromosomal abnormalities.
We collected these data and calculated the NNS for adverse preg-
nancy outcomes. The NNS for miscarriage in men with azoospermia
is 80–88 and for a child with CA 790–3951. In men with non-
azoospermia the NNS for miscarriage is 315–347 and for a child
with CA, 2543–12 723.
The most important consequence of genetic abnormalities in men
with a procreative wish is the increased risk of a child with CA due
to an unbalanced chromosomal abnormality. In the general popula-
tion, the risk of a child with any CA is estimated to be 2–3%. Most
gonosomal abnormalities may cause infertility in the offspring, but
no other CA. The risk of CA is increased in translocations and
some pericentric inversions, and the precise risk estimation is based
on which chromosomes are involved and the breakpoints of the
chromosomal anomaly. Worldwide published data on this risk estima-
tion are used to counsel the couple on their speciﬁc risk. The estima-
tion can be very precise when the abnormality is relatively common.
However, for most abnormalities, no data for calculating the risk are
available. We did not ﬁnd a signiﬁcant difference in the incidence of
children with CA born to infertile men with and without chromosomal
abnormalities. This is probably caused by the small number of preg-
nancies in our study in the men with chromosomal abnormalities.
For the calculation of an NNS, we therefore used the theoretical
risk of a child with CA in these men, based on the literature.
Because in the study period only ART with ejaculated sperm could
be offered in our clinic, only the couples with non-azoospermia
have undergone ART and conceived. Based on the data obtained in
our study, the NNS for a child with CA is 2543–12 723 in men
with non-azoospermia. If ICSI with surgically retrieved sperm is per-
formed in azoospermic men with genetic abnormalities, the risk for
........................................................................................
Table III Pregnancy outcomes in 38 couples in which
the male partner had a chromosomal abnormality,
categorized to its association with miscarriage and
offspring with CAs.
Total % NI % M1M
and CA
%
Number of couples 38 24 14
(3 + 11)

















































At least one normal







NI: Chromosomal abnormality without increased risk for miscarriage or a child with
congenital anomalies; M + M and CA: Sum of categories M: Chromosomal
abnormality with increased risk of miscarriage only, and M and CA: Chromosomal
abnormality with increased risk of miscarriage and child with congenital anomalies.
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the offspring is expected to remain low since most genetic abnormal-
ities found in azoospermic men are not associated with miscarriage or
children with CA. If we extrapolate the results of this study to men
with azoospermia, the NNS for a child with CA in azoospermic
men would be 790–3951.
Another consequence of chromosomal abnormalities can be an
increased risk (in reviews varying from 49 to 83%) of miscarriages, es-
pecially in translocations and pericentric inversions (Franssen et al.,
2006; Stephenson and Sierra, 2006; Suzumori and Sugiura-Ogasawara,
2010). In our study, ART treatment of non-azoospermic men with
chromosomal anomalies did not result in signiﬁcantly more miscar-
riages (32.4%), when compared with men with a normal karyotype
(25.1%). Based on our data, the NNS for miscarriage in infertile
men is 265–291 (80–88 for azoospermic men and 315–347 for non-
azoospermic men). In non-azoospermic men, it might be more cost-
effective to limit screening for chromosomal abnormalities to those
with a history of more than one miscarriage. In recurrent miscarriage,
the risk that one of the partners of a couple is a carrier of a transloca-
tion or inversion is 4–6% (Goddijn and Leschot, 2000), while in our
study the prevalence of chromosomal abnormalities with an increased
risk of miscarriages was only 1.0% for the male partner with non-
azoospermia. A higher prevalence of structural chromosomal abnor-
malities, as in couples with recurrent miscarriages, might lower the
NNS substantially. The low prevalence of translocations and inversions
among infertile men indicates that male infertility alone is not the most
effective selection criterion for genetic screening. It remains to be
established whether a positive history for recurrent miscarriage or a
positive family history for recurrent miscarriage or children with CA
decreases the NNS signiﬁcantly in non-azoospermic infertile men. Re-
search on the impact of recurrent miscarriages in relatives on the NNS
might be hampered by non-disclosure of miscarriages, which may be
culturally determined.
Most non-azoospermic men in our cohort with an increased risk of
unbalanced progeny did not refrain from ART after counselling, and
conceived. This did not result in a signiﬁcantly higher incidence of mis-
carriages or offspring with CAs when compared with infertile men
with a chromosomal abnormality without a known increased risk for
adverse pregnancy outcome. This may indicate that screening for
chromosomal abnormalities in non-azoospermic men does not de-
crease the incidence of adverse pregnancy outcomes.
Screening for chromosomal abnormalities, and also for AZF dele-
tions, in men with poor sperm quality may serve another goal: it
might give an explanation for the infertility, as in some chromosomal
abnormalities (e.g. Klinefelter’s syndrome and Robertsonian transloca-
tions), and in AZF a and b deletions the association with infertility is
well-known. A causative diagnosis may be helpful in the emotional
coping process of the couple. Furthermore, in some countries, legisla-
tion prescribes testing for genetic causes in all infertile couples. This
may include testing for cystic ﬁbrosis-related and androgen receptor
gene mutations, as well as other gene mutations and polymorphisms
suspected to be involved in infertility (O’Flynn O’Brien et al., 2010).
Most guidelines advise the screening of infertile men for chromosomal
abnormalities and AZF deletions and the performance of elaborate
testing based on the clinical presentation. We explored the efﬁciency
of the common policy of screening for chromosomal abnormalities
and AZF deletions, in terms of ﬁnding the cause of the male infertility
(Supplementary data, Table SI). We found that most genetic abnor-
malities detected in azoospermic men had a known association with
infertility, while the majority of genetic abnormalities found in non-
azoospermic men were chance ﬁndings (i.e. those occurring with a
low frequency in the population and unrelated to the infertility of
the couple). In our study, azoospermia was most frequent in men
with gonosomal abnormalities (including AZF deletions) and Robert-
sonian translocations, while the majority of men with reciprocal
Figure 1 Prevalence (95% conﬁdence intervals) of chromosomal abnormalities and NNS for miscarriage (M) and child with CAs in a cohort of
infertile men.
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translocations and inversions were non-azoospermic. This is in agree-
ment with the literature (reviewed in O’Flynn O’Brien et al., 2010).
For the development of evidence-based guidelines on the genetic
screening of infertile men cost-effectiveness, analyses have to be per-
formed that also consider the costs of adverse outcomes of pregnan-
cies, and the costs of prevention of miscarriages and children with CAs
by preimplantation genetic diagnosis and prenatal diagnosis. The
current study provides data on the NNS for these adverse outcomes,
to be used in future cost-effectiveness studies. The NNS in men with
azoospermia for miscarriage (80–88) and for a child with CA (790–
3951) are relatively low compared with men with non-azoospermia,
in whom the NNS for miscarriage is 315–347 and the NNS for a
child with CA is 2543–12 723. The large difference in these NNS
between men with azoospermia and non-azoospermia is caused by
the signiﬁcant difference in the prevalence of chromosomal abnormal-
ities in these two groups of infertile men. The probability of ﬁnding a
chromosomal abnormality is even higher in men with non-obstructive
azoospermia compared with men with obstructive azoospermia
(O’Flynn O’Brien et al., 2010). As a consequence, the NNS in men
with non-obstructive azoospermia will be substantially lower. Due
to the retrospective design of our study, this subcategorization of
azoospermia was not possible. Future studies should address this
issue, to allow for a better risk estimate in obstructive and non-
obstructive azoospermia.
Based on the NNS found in our study, we recommend performing
chromosomal screening in all azoospermic men, because a relatively
low number of men need to be screened to prevent adverse preg-
nancy outcomes. In non-azoospermic infertile men, screening might
be limited to men with a history of recurrent miscarriage or with a
positive family history for recurrent miscarriage or children with
CAs. Future cost-effectiveness studies are needed to provide further
evidence that will aid in the development of guidelines on screening
infertile men for chromosomal abnormalities.
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